Evotec Extends Medicinal Chemistry Collaboration with Ono
Pharmaceutical Co., Ltd.
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ - Evotec extends its research collaboration with Ono to include anion channel target -Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ:EVTC) today announced that it has extended its current researchcollaboration with Ono Pharmaceutical Co., Ltd. (Ono) and initiated anew discovery collaboration. Under the contract extension Evotec willprovide integrated drug discovery activities, including highthroughput screening, medicinal chemistry and in vitro pharmacologyto discover novel, small molecular weight compounds active against anion channel target selected by Ono. Ono will access Evotec's ionchannel drug discovery platform and expertise and Evotec will receiveresearch funding and milestone payments.Evotec and Ono have collaborated since March 2008 identifying novelinhibitors for a protease target. Within this collaboration Evotecprovides protein crystallography, medicinal chemistry, biology andADMET services to Ono with the aim of progressing a compound towardsclinical development."Since we have a high regard for Evotec's wide range of drugdiscovery technologies, and the existing collaboration with Evotectargeting a protease has progressed as planned, we are now pleased toenter into a new drug discovery agreement on an ion channel withEvotec utilizing their proprietary drug discovery platform. Weanticipate the collaboration will result in identifying a novel drugcandidate with a high potential" said Kazuhito Kawabata, Ph.D.,Managing Director, Research Headquarters at Ono.Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Weare delighted to be expanding our collaboration and initiating a newdiscovery collaboration with Ono, a partner with whom we enjoy aclose relationship. This expansion clearly demonstrates the value webring to our alliance partners in the area of drug discovery. We lookforward to continuing working closely with our colleagues at Ono."Contact Evotec AG:Dr Werner Lanthaler, Chief Executive Officer, Phone:+49.(0)40.56081-242, werner.lanthaler(at)evotec.comForward-looking statementsInformation set forth in this press release contains forward-lookingstatements, which involve a number of risks and uncertainties. Suchforward-looking statements include, but are not limited to,statements about our expectations and assumptions concerningregulatory, clinical and business strategies, the progress of ourclinical development programs and timing of the results of ourclinical trials, strategic collaborations and management's plans,objectives and strategies. These statements are neither promises norguarantees, but are subject to a variety of risks and uncertainties,many of which are beyond our control, and which could cause actualresults to differ materially from those contemplated in theseforward-looking statements. In particular, the risks anduncertainties include, among other things: risks that the Company maybe unable to reduce its cash burn through recent restructuring andcost containment measures and may not recognize the results of suchmeasures within the expected timeframe; risks that product candidatesmay fail in the clinic or may not be successfully marketed ormanufactured; the risk that we will not achieve the anticipatedbenefits of our collaborations, partnerships and acquisitions in thetimeframes expected, or at all; risks relating to our ability toadvance the development of product candidates currently in thepipeline or in clinical trials; our inability to further identify,develop and achieve commercial success for new products andtechnologies; the risk that competing products may be moresuccessful; our inability to interest potential partners in ourtechnologies and products; our inability to achieve commercialsuccess for our products and technologies; our inability to protectour intellectual property and the cost of enforcing or defending ourintellectual property rights; our failure to comply with regulationsrelating to our products and product candidates, including FDArequirements; the risk that the FDA may interpret the results of ourstudies differently than we have; the risk that clinical trials maynot result in marketable products; the risk that we may be unable tosuccessfully secure regulatory approval of and market our drugcandidates; and risks of new, changing and competitive technologiesand regulations in the U.S. and internationally.The list of risks above is not exhaustive. Our most recent AnnualReport on Form 20-F, filed with the Securities and ExchangeCommission, and other documents filed with, or furnished to theSecurities and Exchange Commission, contain additional factors thatcould impact our businesses and financial performance. We expresslydisclaim any obligation or undertaking to release publicly anyupdates or revisions to any such statements to reflect any change inour expectations or any change in events, conditions or circumstanceson which any such statement is based.http://hugin.info/131215/R/1347676/324088.pdf --- End of Message ---Evotec AGSchnackenburgallee 114 Hamburg GermanyWKN: 566480; ISIN: DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All Share;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 15.10.2009 - 08:31 Uhr
Sprache: Deutsch
News-ID 6943
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Evotec Extends Medicinal Chemistry Collaboration with Ono
Pharmaceutical Co., Ltd."
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
